Chih-jen F. Yang

Kaohsiung, KHQ, Taiwan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 147 publications

Local consolidative therapy after EGFR-TKI response in advanced EGFR-mutant NSCLC.

Local consolidative therapy after EGFR-TKI response in advanced EGFR-mutant NSCLC.

Journal: Future oncology (London, England)

Published: June 19, 2026

Stage shifts in national lung adenocarcinoma and the impact of opportunistic self-initiated LDCT screening in Taiwan: a nationwide population-based cohort study.

Stage shifts in national lung adenocarcinoma and the impact of opportunistic self-initiated LDCT screening in Taiwan: a nationwide population-based cohort study.

Journal: The Lancet regional health. Western Pacific

Published: January 29, 2026

Surgical strategy and prognostic factors in very elderly (≥ 75 Years) patients with stage I NSCLC: insights from a propensity score-matched analysis.

Surgical strategy and prognostic factors in very elderly (≥ 75 Years) patients with stage I NSCLC: insights from a propensity score-matched analysis.

Journal: BMC pulmonary medicine

Published: December 07, 2025

Gender and Educational Pathway Differences in 360-Degree Evaluations During Postgraduate Year Training in Taiwan.

Gender and Educational Pathway Differences in 360-Degree Evaluations During Postgraduate Year Training in Taiwan.

Journal: Journal of medical education and curricular development

Published: November 12, 2025

Clinicopathologic Predictors of Outcome and Implications for Adjuvant Therapy in Pathologic Stage II Non-small Cell Lung Cancer.

Clinicopathologic Predictors of Outcome and Implications for Adjuvant Therapy in Pathologic Stage II Non-small Cell Lung Cancer.

Journal: Anticancer research

Published: October 20, 2025

First-Line Afatinib 30 mg Versus 40 mg in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutations: Real-world Efficacy and Tolerability in Taiwan.

First-Line Afatinib 30 mg Versus 40 mg in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutations: Real-world Efficacy and Tolerability in Taiwan.

Journal: Anticancer research

Published: October 13, 2025

Integrative Analysis of Glycosylation-Related Genes Reveals Prognostic Subtypes, Immune Evasion, and Therapeutic Vulnerabilities in Lung Adenocarcinoma.

Integrative Analysis of Glycosylation-Related Genes Reveals Prognostic Subtypes, Immune Evasion, and Therapeutic Vulnerabilities in Lung Adenocarcinoma.

Journal: Oncology research

Published: September 30, 2025

Combination therapy of sotorasib and docetaxel overcomes resistance to sotorasib alone in KRAS G12C mutant lung adenocarcinoma.

Combination therapy of sotorasib and docetaxel overcomes resistance to sotorasib alone in KRAS G12C mutant lung adenocarcinoma.

Journal: Journal of chemotherapy (Florence, Italy)

Published: May 12, 2025

Clinical Outcomes of Different Generation EGFR TKIs in Susceptible EGFR-Mutated Advanced Nonsmall-Cell Lung Cancer.

Clinical Outcomes of Different Generation EGFR TKIs in Susceptible EGFR-Mutated Advanced Nonsmall-Cell Lung Cancer.

Journal: The Kaohsiung journal of medical sciences

Published: May 07, 2025

Prognostic significance of tumor spread through air spaces and lymphovascular invasion in stage I non-small cell lung cancer: implications for adjuvant chemotherapy.

Prognostic significance of tumor spread through air spaces and lymphovascular invasion in stage I non-small cell lung cancer: implications for adjuvant chemotherapy.

Journal: World journal of surgical oncology

Published: March 23, 2025

The complex interplay of TROP2 and PD-L1 in immune regulation and drug resistance in lung cancer.

The complex interplay of TROP2 and PD-L1 in immune regulation and drug resistance in lung cancer.

Journal: American journal of cancer research

Published: March 14, 2025

Successful Treatment of Osimertinib Resistance in an EGFR-Mutant Lung Cancer Patient With a Rare STRN3-ALK Fusion Using Brigatinib and Osimertinib.

Successful Treatment of Osimertinib Resistance in an EGFR-Mutant Lung Cancer Patient With a Rare STRN3-ALK Fusion Using Brigatinib and Osimertinib.

Journal: The Kaohsiung journal of medical sciences

Published: February 24, 2025

Showing 1-12 of 147

Last Updated: 09/26/2026